Genetic diversity of human immunodeficiency viruses and antiretroviral therapy
- Authors: Bobkova MR1
-
Affiliations:
- Issue: Vol 88, No 11 (2016)
- Pages: 103-111
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/32113
- DOI: https://doi.org/10.17116/terarkh20168811103-111
- ID: 32113
Cite item
Full Text
Abstract
The lecture is devoted to the analysis of the state-of-the-art of the impact of genetic diversity of human immunodeficiency (HIV) viruses on the pattern of infection and the efficiency of antiretroviral therapy (ART). It provides brief information on the origin and evolution of HIV and on the current classification of their genetic variants. The molecular epidemiological situation of HIV infection in Russia and nearby states and the major molecular HIV variants that are dominant in these countries, as well as their origin and prevalence trends are characterized. How the diversity of HIV can affect the efficiency of diagnosis, the transmission of the virus, and the pattern of HIV pathogenesis are briefly reviewed. The comparative data available in the world’s scientific literature on these topics are given. More detailed attention is given to the possible causes of varying therapeutic effects against different HIV subtypes, as well as to the specific features of the formation and phenotyping manifestation of ART drug resistance mutations. There is evidence for the necessity of forming a unified follow-up system for treated HIV-infected patients during ART scaling, including in an effort to evaluate the impact of the specific features of the HIV genome on the efficiency of treatment regimens used in Russia.
Keywords
References
- Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends molmed. 2012;18(3):182-192. doi: 10.1016/j.molmed.2011.12.001
- Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br med bull. 2001;58:19-42.
- Ndung’u T, Weiss RA. On HIV diversity. AIDS (London, England). 2012;26(10):1255-1260. doi: 10.1097/QAD.0b013e32835461b5
- Vuilleumier S, Bonhoeffer S. Contribution of recombination to the evolutionary history of HIV. Cur Opin HIV AIDS. 2015;10(2):84-89. doi: 10.1097/COH.0000000000000137
- Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harbor Perspectives Med. 2011;1(1):a006841. doi: 10.1101/cshperspect.a006841
- Bártolo I, Taveira N. HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy. In: Caliskan M, ed. Genetic Diversity in Microorganisms. InTech; 2012.
- Maljkovic Berry I, Ribeiro R, Kothari M, Athreya G, Daniels M, Lee HY, Bruno W, Leitner T. Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases. J Virol. 2007;81(19):10625-10635. doi: 10.1128/JVI.00985-07
- Eberle J, Gurtler L. HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies. Intervirology. 2012;55(2):79-83. doi: 10.1159/000331993
- Peeters M, D’Arc M, Delaporte E. Origin and diversity of human retroviruses. AIDS Rev. 2014;16(1):23-34.
- Santoro MM, Perno CF. HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol. 2013;2013:481314. doi: 10.1155/2013/481314
- Diez-Fuertes F, Cabello M, Thomson MM. Bayesian phylogeographic analyses clarify the origin of the HIV-1 subtype A variant circulating in former Soviet Union’s countries. MEEGID. 2015;33:197-205. doi: 10.1016/j.meegid.2015.05.003
- Bobkova M. Current status of HIV-1 diversity and drug resistance monitoring in the former USSR. AIDS Rev. 2013;15(4):204-212.
- Bobkov AF, Kazennova EV, Selimova LM, Khanina TA, Ryabov GS, Bobkova MR, Sukhanova AL, Kravchenko AV, Ladnaya NN, Weber JN, Pokrovsky VV. Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J Med Virol. 2004;74(2):191-196. doi: 10.1002/jmv.20177
- Бобкова М.Р., Буравцова Е.В., Суханова А.Л., Ольховский И.А., Бобков А.Ф., Покровский В.В.. Применение тест-системы Amplicor HIV-1 для диагностики ВИЧ-инфекции у новорожденных детей в России: первые результаты (2001—2002 гг.). Клиническая лабораторная диагностика. 2003;6:49-53.
- Bogh M, Machuca R, Gerstoft J, Pedersen C, Obel N, Kvinesdal B, Nielsen H, Nielsen C. Subtype-specific problems with qualitative Amplicor HIV-1 DNA PCR test. J Clin Virol. 2001;20(3):149-153.
- Obaro SK, Losikoff P, Harwell J, Pugatch D. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr Infect Dis J. 2005;24(2):183-184.
- Luft LM, Gill MJ, Church DL. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. International journal of infectious diseases: IJID. 2011; 15(10):e661-670. doi: 10.1016/j.ijid.2011.05.013
- Hudgens MG, Longini IM, Jr., Vanichseni S, Hu DJ, Kitayaporn D, Mock PA, Halloran ME, Satten GA, Choopanya K, Mastro TD. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol. 2002;155(2):159-168.
- Kiwanuka N, Laeyendecker O, Quinn TC, Wawer MJ, Shepherd J, Robb M, Kigozi G, Kagaayi J, Serwadda D, Makumbi FE, Reynolds SJ, Gray RH. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS (London, England). 2009;23(18):2479-2484. doi: 10.1097/QAD.0b013e328330cc08
- Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J virol. 2007;81(15):7885-7893. doi: 10.1128/JVI.00218-07
- Yang C, Li M, Newman RD, Shi YP, Ayisi J, van Eijk AM, Otieno J, Misore AO, Steketee RW, Nahlen BL, Lal RB. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS (London, England). 2003;17(11):1667-1674. doi: 10.1097/01.aids.0000060412.18106.d4
- John-Stewart GC, Nduati RW, Rousseau CM, Mbori-Ngacha DA, Richardson BA, Rainwater S, Panteleeff DD, Overbaugh J. Subtype C Is associated with increased vaginal shedding of HIV-1. Journal Infect Dis. 2005;192(3):492-496. doi: 10.1086/431514
- Martinez AM, Hora VP, Martinez AL, Mendoza-Sassi R, Von Groll A, Soares EA, D’Avila N, Silveira J, Leal RG, Tanuri A, Soares MA, Unit HA. Determinants of HIV-1 mother-to-child transmission in Southern Brazil. Anais da Academia Brasileira de Ciencias. 2006;78(1):113-121. doi: 10.1590/s0001-37652006000100011
- Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (London, England). 2009;23(11):1397-1404. doi: 10.1097/QAD.0b013e32832b7dca
- Easterbrook PJ, Smith M, Mullen J, O’Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Society. 2010;13:4. doi: 10.1186/1758-2652-13-4
- Pant Pai N, Shivkumar S, Cajas JM. Does genetic diversity of HIV-1 non-B subtypes differentially impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evidence: 1996—2010. J Acquired Immune Deficiency Syndromes. 2012;59(4):382-328. doi: 10.1097/QAI.0b013e31824a0628
- Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E, Ronald A, Clifford DB, Laeyendecker O, Quinn TC. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009;49(5):780-786. doi: 10.1086/605284
- Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H, Berman JW, Ranga U, Tyor WR, Prasad VR. HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neuroscie. 2008;28(40):10010-10016. doi: 10.1523/JNEUROSCI.2955-08.2008
- Bartolo I, Abecasis AB, Borrego P, Barroso H, McCutchan F, Gomes P, Camacho R, Taveira N. Origin and epidemiological history of HIV-1 CRF14_BG. PloS ONE. 2011;6(9):e24130. doi: 10.1371/journal.pone.0024130
- Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, Eller LA, Eller M, Makumbi F, Birx D, Wabwire-Mangen F, Serwadda D, Sewankambo NK, Quinn TC, Wawer M, Gray R. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197(5):707-713. doi: 10.1086/527416
- De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS (London, England). 2004;18(17):2330-2331.
- Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, Weber JN. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS (London, England). 2002;16(8):1139-1146.
- Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D, Resistance UKCGoHD. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin infect dis. 2009;48(9):1296-1305. doi: 10.1086/598502
- Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, Burgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Gunthard HF, Swiss HIVCS. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis. 2011;53(11):1143-1152. doi: 10.1093/cid/cir669
- Grossman Z, Schapiro JM, Levy I, Elbirt D, Chowers M, Riesenberg K, Olstein-Pops K, Shahar E, Istomin V, Asher I, Gottessman BS, Shemer Y, Elinav H, Hassoun G, Rosenberg S, Averbuch D, Machleb-Guri K, Kra-Oz Z, Radian-Sade S, Rudich H, Ram D, Maayan S, Agmon-Levin N, Sthoeger Z. Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes. PloS ONE. 2014;9(1):e86239. doi: 10.1371/journal.pone.0086239
- Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, Strohmaier KM, Leavitt RY, Nguyen BY. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS (London, England). 2011;25(11):1365-1369. doi: 10.1097/QAD.0b013e328348065a
- Vingerhoets J, Azijn H, Tambuyzer L, Dierynck I, De Meyer S, Rimsky L, Nijs S, De Smedt G, de Bethune MP, Picchio G. Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data. AIDS Res Hum Retrovir. 2010;26(6):621-624. doi: 10.1089/aid.2009.0239
- Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, de Bethune MP, Picchio G. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antiviral ther. 2010;15(8):1161-1169. doi: 10.3851/IMP1697
- Gatell JM. Antiretroviral therapy for HIV: do subtypes matter? Clin Infect Dis. 2011;53(11):1153-1155. doi: 10.1093/cid/cir686
- Tuaillon E, Gueudin M, Lemee V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J AIDS. 2004;37(5):1543-1549.
- Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(22):14410-14415. doi: 10.1073/pnas.222366699
- Kinomoto M, Appiah-Opong R, Brandful JA, Yokoyama M, Nii-Trebi N, Ugly-Kwame E, Sato H, Ofori-Adjei D, Kurata T, Barre-Sinoussi F, Sata T, Tokunaga K. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis. 2005;41(2):243-251. doi: 10.1086/431197
- Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Cur Opin Virol. 2012;2(5):636-643. doi: 10.1016/j.coviro.2012.08.006
- Rhee SY, Sankaran K, Varghese V, Winters M, Hurt CB, Eron JJ, Parkin N, Holmes SP, Holodniy M, Shafer RW. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol. 2016; [Epub ahead of print]. doi: 10.1128/JVI.00495-16
- Бобкова М.Р. Лекарственная устойчивость ВИЧ. М.: Человек; 2014.
- Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T, Cellerai C, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Gunthard HF, Swiss HIVCS. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS ONE. 2012;7(6):e37983. doi: 10.1371/journal.pone.0037983
- Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM, Database UHDR, study UC. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS (London, England). 2013;27(14):2245-2253. doi: 10.1097/QAD.0b013e3283636179
- Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther. 2009;3(6):583-594. doi: 10.2217/hiv.09.40
- Kolomeets AN, Varghese V, Lemey P, Bobkova MR, Shafer RW. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS (London, England). 2014;28(17):F1-8. doi: 10.1097/QAD.0000000000000485
- Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2010;54(11):4812-4824. doi: 10.1128/AAC.00829-10
- Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, Diaz RS, Herchenroder O, Soares MA, Arts EJ. Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility. Antimicrob Agents Chemother. 2012;56(5):2719-2725. doi: 10.1128/AAC.06079-11
- Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, Moisi D, Mendelson E, Grossman Z, Brenner BG. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. Antimicrob Agents Chemother. 2012;67(4):988-994. doi: 10.1093/jac/dkr582
- Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS (London, England). 2010;24(14):2171-2179. doi: 10.1097/QAD.0b013e32833cf265
- Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antiviral Chem Chemother. 2010;20(3):117-131. doi: 10.3851/IMP1443
- Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, Ram D, Petropoulos CJ, Schapiro JM. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother. 2004;48(6):2159-2165. doi: 10.1128/AAC.48.6.2159-2165.2004